Inhibition of tumor angiogenesis through modulation of vascular endothelial growth factor (VEGF) and its signaling pathway has been clinically validated as a viable therapeutic modality in the treatment of cancer. The use of artificial transcription factors based on Cys2-His2 zinc-finger proteins (ZFPs) targeting the VEGF promoter offers a novel strategy for modulating VEGF levels in tumors. In order to demonstrate the utility of VEGFtargeted ZFPs as therapeutic agents, we generated adenoviruses (Ads) expressing VEGF promoter-targeted transcriptional repressor ZFP, F435-KOX. A replicationincompetent Ad expressing F435-KO X, namely, Ad-∆E1-KOX, significantly reduced VEGF expression and functionally led to inhibition of angiogenesis. In vivo, an oncolytic Ad expressing F435-KOX, namely, Ad-∆B7-KOX, elicited a pronounced antitumor effect against a human glioblastoma xenograft model, U87MG. Further, consistent with its expected mechanism of action, Ad-∆B7-KOX was shown to greatly reduce the level of VEGF and vessel density in tumor tissue and increase terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL)-positive apoptotic cells in tumors. Survival rates were also significantly increased in Ad-ΔB7-KOX-treated mice. Taken together, the findings from this study identify F435-KOX as a novel and potent ZFP transcription factor that can inhibit VEGF-A-mediated angiogenesis and offer a novel therapeutic modality in the treatment of cancer.
IntroductIon
Vascular endothelial growth factor (VEGF) has been demonstrated to be one of the dominant drivers of angiogenesis and, in this capacity, it plays a prominent role in tumor growth and progression. 1, 2 Because blood supply is indispensable for tumor growth, inhibition of angiogenesis has been clinically validated as a therapeutic modality in cancer therapy. 3 However, systemic administration of angiogenic inhibitors is associated with intrinsic drawbacks including the necessity for repeated and long-term administrations in order to maintain tumor suppression, the increased risk of toxicity, and the high expense. 4 Antiangiogenic gene therapy offers a unique opportunity to overcome some of these limitations. The advantages of this modality of treatment include: sustained highlevel expression after a single application, the ability to deliver more than one transgene by using bi-or tricistronic vectors, and possible cost reduction. 5 A study using an angiostatin-expressing replication-incompetent adenovirus (Ad) demonstrated inhibition of tumor growth following a single injection into a human U87MG glioma xenograft model. 6 However, replication-deficient viral vectors have inherent limitations, including short duration of therapeutic gene expression and restricted transduction efficiency. In order to overcome these shortcomings, oncolytic Ads have been adopted as the latest vehicle of delivery in gene therapy. Recently, our group reported that E1A-and E1B-double mutant replicationcompetent Ad, namely, Ad-ΔB7, elicits significant antitumor effect and viral replication in a cancer cell-specific manner. 7 Ad-ΔB7 is expected to elicit an amplification of its effect, in which the replicating vector would be able to infect cells and, subsequently, deliver the therapeutic gene to adjacent cancer cells.
A key application characteristic that any gene therapy approach must possess is that it targets gene expression in a highly specific manner. In nature, targeted transcriptional regulation is accomplished by the action of transcription factors. Transcription factors contain two functionally distinct domains: a specific DNA-binding domain that recognizes specific regulatory elements in the target genes, and an effector domain that regulates or recruits various components of protein machinery that instruct transcription. 8 The highly adaptable Cys2-His2 zinc-finger proteins (ZFPs) constitute the largest family of eukaryotic transcription factors. 9 Because of their diversity and modular structure, Cys2-His2 ZFPs provide an ideal framework for creating diverse artificial transcription factors.
www.moleculartherapy.org vol. 16 no. 6 june 2008 chromosomal genes through engineered ZFPs, using customdesigned DNA sequence specificities. 11, [12] [13] [14] In this study, we investigated the potential of a novel transcriptional repressor (termed F435-KOX) based on ZFPs designed to target the endogenous VEGF-A promoter and tumor angiogenesis. Our results show that F435-KOX is a potent ZFP transcription factor that can inhibit VEGF-A-mediated angiogenesis. Further, we demonstrate, for the first time, the effectiveness of augmenting the antitumor effect and survival benefit with oncolytic Ad expressing VEGF promoter-targeted ZFP, F435-KOX.
results

F435-KoX-expressing Ads downregulate the expression of VeGF in cell culture
Given that the expression of VEGF-A is affected by replicationcompetent Ads expressing adenoviral early gene E1A, [15] [16] [17] we generated an E1-deleted replication-incompetent Ad expressing F435-KOX, namely, Ad-∆E1-KOX (Figure 1a) , in order to investigate whether F435-KOX would specifically suppress VEGF-A expression. F435-KOX had been constructed earlier by fusing the F435 ZFP (which was engineered to recognize two almost identical 9-base pair DNA sequences in the promoter of the human VEGF-A gene) to the Kruppel-associated box repression domain derived from the human protein KOX1. 14, 18 As shown in Figure 2 , dose-dependent decrease in VEGF protein levels was seen in both the cancer cell lines that were transduced with Ad-∆E1-KOX. More specifically, Ad-∆E1-KOX almost completely knocked down VEGF expression in the U343 cells at multiplicities of infection (MOIs) of ≥5, and this was also true in U87MG cells at MOIs of ≥20. Together, these data show that the F435-KOXexpressing replication-incompetent Ad, Ad-∆E1-KOX, reduces VEGF expression with high efficiency.
Ad-∆e1-KoX inhibits angiogenesis in vitro and ex vivo
In order to verify the antiangiogenic effect of F435-KOX, we examined its effect on suppressing capillary tube formation of human umbilical vein endothelial cell (HUVEC) cells in vitro. Visually, no organized structures could be seen for cells treated with Ad-∆E1-KOX-infected conditioned medium, and the relative tube length was inhibited by 56.4% as compared to that of Ad-∆E1-GFP (P < 0.001) (Figure 3a and b) . However, treatment with the conditioned medium collected from untreated and Ad-∆E1-GFP-infected cells led to the formation of organized, elongated, tube-like structures resembling capillaries with an extensive network (Figure 3a) . There was a similar finding for cells in the presence of Ad-∆E1-KOX-infected U87MG-conditioned medium (Figure 3a and b) . We next determined whether F435-KOX expression from Ad-∆E1-KOX Ad could inhibit microvessel outgrowth from rat aortic rings (explants) embedded in Matrigel beds. As shown in Figure 4a , active vessel sprouting was observed within 7 days in aortic rings cultured with U87MG cells' conditioned medium. In contrast, the aortic rings cultured with conditioned medium of Ad-∆E1-KOX-infected cells developed little or no outgrowth of the sprouts, showing a 77.3% (P < 0.001) and 70.6% (P < 0.05) decrease in the number of microvessels as compared to untransduced and Ad-∆E1-GFPtransduced conditioned media, respectively (Figure 4b ). These data confirmed and extended our in vitro findings of the potent antiangiogenic effect induced by Ad-∆E1-KOX.
F435-KoX expression inhibits viral replication, but increases the cancer cell-specificity
In order to enhance the potency induced by the antiangiogenic effect of F435-KOX, we constructed a F435-KOX-expressing replication-competent oncolytic Ad, Ad-ΔB7-KOX (Figure 1b) order to examine whether virally expressed F435-KOX altered the cytopathic effect of replicating Ad, a cytopathic effect assay was carried out. As seen in Figure 5 , in all cancer cell lines tested the virally induced cytopathic effect appeared to be similar for Ad-ΔB7-KOX and Ad-ΔB7. In marked contrast, the cytopathic effect of Ad-ΔB7-KOX was approximately three-to tenfold attenuated compared to that of Ad-ΔB7 in normal cells, thereby demonstrating the cancer cell-specificity of Ad-ΔB7-KOX. Next, the kinetics of viral replication of Ad-ΔB7-KOX and of Ad-ΔB7 were compared. As shown in Figure 6a , the total viral yield of Ad-ΔB7-KOX was substantially lower, showing about 16-and 48-fold lower levels than Ad-ΔB7 at 24 and 48 hours after infection, respectively, thereby indicating that the expression of F435-KOX had a detrimental effect on viral growth. We next investigated the effect of decreased viral replication of Ad-ΔB7-KOX on VEGF gene expression. When VEGF enzyme-linked immunosorbent assay was carried out using conditioned media from the experiment described earlier, the levels of VEGF secreted were significantly reduced, both in the cells infected with Ad-ΔB7 and in those infected with Ad-ΔB7-KOX (Figure 6b ). This result is in agreement with those obtained earlier, showing that E1A protein in replicating Ad downregulates VEGF expression. More importantly, Ad-ΔB7-KOX was more effective in suppressing VEGF expression than its cognate control oncolytic Ad, Ad-ΔB7, even though the E1A level of Ad-ΔB7-KOX was significantly lower than that of Ad-ΔB7, thereby demonstrating the potent antiangiogenic effect of F435-KOX.
Inhibition of VeGF expression by F435-KoX increases cancer cell apoptosis
In order to investigate the mechanism of decreased viral propagation from the expression of F435-KOX, cells infected with either Ad-ΔB7 or Ad-ΔB7-KOX were examined using fluorescence-activated cell sorting analysis. As depicted in Figure 7a , an increase in the subG1 phase cell content was observed after infection with F435-KOXexpressing Ad-ΔB7-KOX (14.3 ± 0.4% and 28.8 ± 2.0% for Ad-ΔB7 and Ad-ΔB7-KOX, respectively), thereby demonstrating that significant numbers of cells were undergoing apoptosis. The induction of apoptosis by F435-KOX-expressing oncolytic Ad was further evaluated using a terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay. After 48 hours, 49.5 ± 11.8% of the Ad-ΔB7-KOX-infected cells were TUNEL-positive, whereas only 4.64 ± 3.21% of the Ad-ΔB7-infected cells were TUNEL-positive (Figure 7b ). This suggests that premature cell lysis caused by the induction of apoptosis in Ad-∆B7-KOX-infected cells may lead to an early viral release, resulting in a decrease in total viral progeny.
enhanced antitumor effect of F435-KoX-expressing oncolytic Ad
We subsequently assessed the antitumor efficacy of Ad-∆B7-KOX in the U87MG human glioma xenograft model. As shown in Figure 8a , phosphate-buffered saline (PBS)-and Ad-∆E1-GFPtreated control tumors increased to an average size of 3,536 ± 455 mm 3 and 3,076 ± 701 mm 3 , respectively, by 25 days after the treatment. In marked contrast, Ad-∆E1-KOX-, Ad-∆B7-, and Ad-∆B7-KOX-treated tumors reached an average size of 1,524 ± 198 mm 3 , 1,211 ± 987 mm 3 , and 502 ± 413 mm 3 , respectively, by the same time-point, representing a decrease of 56.9, 65.7, and 85.8% in tumor volume, respectively, relative to the PBS-treated control mice. Moreover, 50.5 and 58.5% decreases in tumor size were achieved when mice were treated with Ad-∆E1-KOX and Ad-∆B7-KOX, relative to the effects on tumor size after treatment with their respective cognate control Ad vectors, Ad-∆E1-GFP and Ad-∆B7, thereby indicating that enhanced antitumor efficacy was contributed by F435-KOX expression. Survival advantage was also significantly enhanced in animals treated with Ad-∆B7-KOX (P < 0.05) (Figure 8b) . By day 40 after treatment, 100% of the animals in the Ad-∆B7-KOX group were still alive, whereas only 42.9 and 50% of the mice treated with Ad-∆E1-KOX and Ad-∆B7, respectively, were alive. These data demonstrate that the oncolytic Ad-mediated F435-KOX expression effectively reduced the tumor growth, resulting in increased survival.
In vivo tunel, histological, and immunohistochemical characterization
Histological analysis was carried out to verify the mechanism of enhanced antitumor activity of F435-KOX-expressing Ads. PBS-, Ad-ΔE1-GFP-, Ad-ΔE1-KOX-, Ad-ΔB7-, and Ad-ΔB7-KOXtreated U87MG xenograft tumors were removed from the animals at day 10 after three sequential treatments. As shown in Figure 8c (hematoxylin and eosin), PBS-and Ad-ΔE1-GFP-treated control tumors displayed a large area of proliferating tumor cells, whereas a marked decrease in the number of proliferating tumor cells was observed in Ad-ΔE1-KOX-, Ad-ΔB7-, and Ad-ΔB7-KOX-treated tumors. Analysis of VEGF expression showed a marked reduction in the protein expression levels in the tumors treated with Ad-ΔE1-KOX, Ad-ΔB7, and Ad-ΔB7-KOX as compared to those in PBS-and Ad-ΔE1-GFP-treated tumors. Similarly, both the number and the sizes of CD31-positive vessels decreased dramatically in Ad-ΔE1-KOX-, Ad-ΔB7-, and Ad-ΔB7-KOX-treated tumors (Figure 8c) . Microvessel density was reduced 2.4-, 2.6-, and 3.7-fold in response to Ad-ΔE1-KOX, Ad-ΔB7, and Ad-ΔB7-KOX treatment, respectively, as compared to the results in the Ad-ΔE1-GFP treatment group (P < 0.001) (Figure 8d) . Moreover, there was U87MG glioma xenograft tumors were grown subcutaneously in the abdomen of nude mice, and were subsequently injected with phosphate-buffered saline (PBS) (white squares), Ad-ΔE1-GFP (black triangles), Ad-ΔE1-KOX (white triangles), Ad-ΔB7 (black circles), or Ad-ΔB7-KOX (white circles). *P < 0.01. Tumor volume was monitored over time (days) after treatment with adenoviruses (Ads). The percentage of surviving mice was determined by monitoring the death of the mice. Tumor size over 2,500 mm 3 was regarded as death. (c) Histological assessment of angiogenesis in the tumor tissues treated with F435-KOX-expressing Ads. Ten days following final Ad administration, mice were sacrificed and the tumor tissues were harvested. Paraffin-embedded tumor sections were stained with hematoxylin and eosin (H&E). These sections are representative of treated mice from four independent experiments. Tumor tissues were also stained with an antibody against vascular endothelial growth factor (VEGF) or platelet endothelial cell adhesion molecule-1 (PECAM-1) and were hematoxylin counter stained. www.moleculartherapy.org vol. 16 no. 6 june 2008 a statistically significant difference between Ad-ΔB7-and Ad-ΔB7-KOX-treated tumors (P < 0.05). Next, in order to determine whether reduced neovascularization in the tumor mass leads to apoptosis of tumor tissue, TUNEL assay was carried out. Tumors treated with Ad-ΔE1-KOX, Ad-ΔB7, and Ad-ΔB7-KOX exhibited a significant increase in the levels of cell apoptosis.
dIscussIon
In this study, we used the VEGF-A-specific ZFP composed of zinc-finger modules derived from the DNA sequences in the human genome. 18 Earlier, ZFP transcription factors have been used to downregulate 19 or upregulate 13, 20 the expression of VEGF-A. These ZFPs, however, had mutations at key positions in a given zinc-finger framework that made the proteins specifically bind to the VEGF-A promoter. Because ZFPs composed of human zinc fingers are less likely to induce a host immune response than would mutated ZFPs, they might be preferable in therapeutic applications. 18 We employed F435-KOX comprised of ZFP moieties and an effector domain (both of which were derived from human proteins) to construct an Ad encoding the VEGF-A-specific transcriptional repressor, and observed a marked downregulation of VEGF-A expression with high efficiency both in vivo and in vitro.
Previous studies have shown that replication-competent Ads suppress tumor angiogenesis through a preserved E1A region. [15] [16] [17] Therefore, we first constructed an E1-deleted replication-incompetent Ad expressing F435-KOX, namely, Ad-∆E1-KOX, in order to determine whether F435-KOX by itself could reduce endogenous VEGF expression in highly vascularized glioblastomas, U87MG and U343. 21 Ad-∆E1-KOX effectively decreased the VEGF expression in a dose-dependent manner. Ad-∆E1-KOX was also highly effective in preventing tube formation of HUVECs in vitro and in inhibiting the sprouting of microvessels from the aorta rings of rats ex vivo, thereby implying that F435-KOX is a potent antiangiogenic factor, and that it blocks multiple steps in the process of angiogenesis. Taken collectively, these data further demonstrate that Ad-mediated expression of VEGF-Aspecific F435-KOX is functionally active and targets the VEGF promoter, ultimately leading to the blockage of several critical steps in angiogenesis.
In order to induce cancer cell-specific long-term expression of F435-KOX, we engineered an oncolytic Ad expressing F435-KOX, namely, Ad-ΔB7-KOX. Ad-ΔB7-KOX appeared to show cancer cell-killing effects comparable to its cognate control, Ad-ΔB7, in cancer cells, but showed less potency in normal cells, thereby demonstrating its enhanced cancer cell-specificity. In addition, viral replication of Ad-ΔB7-KOX was substantially attenuated as compared to Ad-ΔB7, resulting in a marked decrease in total viral progeny. Also, downregulation of VEGF by the expression of F435-KOX led to the induction of apoptosis. These results are in good agreement with previous findings that show the direct interference of viral multiplication by apoptosis. [22] [23] [24] These findings suggest that premature lysis of the Ad-ΔB7-KOX virus-infected cancer cells by induction of apoptosis led to the subsequent reduction in viral multiplication. The Ad-ΔB7-KOX-induced cytopathic effects in normal cells, however, were significantly lower. This result implies that the F435-KOX expressed from the oncolytic Ad effectively suppressed the level of VEGF in cancer cells (which express high concentration of VEGF), but not in normal cells (which express low levels of VEGF), effectively augmenting the cancer cell-specificity of Ad-ΔB7-KOX oncolytic Ad.
In vivo, Ad-ΔB7-KOX showed enhanced antitumor effect as well as a survival benefit as compared to both Ad-ΔB7 and Ad-∆E1-KOX. The quantum of contribution that the antiangiogenic effect of F435-KOX makes to the inhibition of tumor growth may be as great as the difference between the inhibition effects produced by Ad-∆E1-GFP versus Ad-∆E1-KOX, or by Ad-ΔB7 versus Ad-ΔB7-KOX. The survival rate was also significantly enhanced in the Ad-ΔB7-KOX-treated mice. A notable finding in the highly vascularized U87MG glioma model is that the Ad-ΔB7-KOX-treated group showed extensive coagulative necrosis because of sudden blockage of blood vessels. The potent effects of Ad-ΔB7-KOX on angiogenesis were also demonstrated in the in vivo xenograft model. The microvessel density was significantly reduced in tumors treated with Ad-∆E1-KOX and Ad-ΔB7 as compared to those treated with Ad-∆E1-GFP. Further, 33.7 and 28.7% reduction in microvessel density was observed in Ad-ΔB7-KOX-treated groups relative to Ad-∆E1-KOX-and Ad-ΔB7-treated groups, respectively. In addition, an analysis of VEGF expression showed a dramatic reduction in tumors treated with Ad-ΔE1-KOX, Ad-ΔB7, or Ad-ΔB7-KOX. In agreement with recent reports from others, and with our earlier reports on the suppression of VEGF-A expression by E1A-expressing oncolytic Ads, [15] [16] [17] the density and the size of vessels in the Ad-ΔB7-treated tumor tissues was also significantly reduced as compared to those in the PBS-treated control groups. These data clearly demonstrate that F435-KOX, expressed by the oncolytic Ad, further suppressed VEGF-A gene expression with high efficiency in tumor tissue, in addition to its E1A-mediated antiangiogenesis effect. Moreover, the in vivo apoptosis analysis revealed an increase in TUNEL-positive apoptotic cells in Ad-∆E1-KOX-, Ad-ΔB7-, and Ad-ΔB7, KOX-treated tumors, consistent with the observed enhanced inhibition of growth in treated tumors. Overall, our findings imply that, in Ad-ΔB7-KOX-treated mice, inhibition of tumor growth is caused, in part, by the reduction in tumor angiogenesis. Earlier, our group 14 and Snowden et al. 19 independently reported that specific engineered ZFP transcription factors can potently inhibit the expression of VEGF-A, but the therapeutic value had not been demonstrated in a therapeutically relevant in vivo xenograft model. It is relevant to note that transient expression of VEGF-specific ZFP transcription factors in cancer cells, through plasmid transfection, resulted in only moderate (up to 80%) suppression of VEGF expression. In this study, we observed almost complete (>99%) suppression of VEGF-A expression in cancer cells with the use of the Ad expressing the same ZFP at relatively low MOIs. Unlike transient expression of F435-KOX, our novel Ad-ΔB7-KOX would allow long-term expression of F435-KOX in a cancer cell-specific manner and would be replenished over time by Ad replication. As demonstrated in our earlier reports, 17 the duration and magnitude of the therapeutic effect following infection with the oncolytic Ad were both greater when compared with the nonreplicating Ad. The therapeutic advantage of Ad-ΔB7-KOX would be enhanced in humans because VEGF-A expression in tumor stromal cells would also be inhibited by this human-specific ZFP transcription factor, F435-KOX. Moreover, the targeting of endothelial cells for tumor therapy is an attractive strategy because vascular endothelial cells are genetically stable and the possibility of their developing resistance through a genetic alteration is low, whereas rapidly proliferating cancer cells have been reported to readily acquire resistance to anticancer therapy.
In gene therapy applications, there are at least three major objectives that are of relevance to the use of artificial transcription factors: maintaining a high level of DNA-binding specificity, achieving a desired level of gene expression in a target cell type, and regulating the activity of the targeted gene only, while avoiding altering the level of expression of other genes. 8 In addressing these points of concern, the F435-KOX-expressing oncolytic Ad has the advantage of being composed of in vivo screened human ZFPs, thereby ensuring high specificity for targeted gene binding. Also, being an oncolytic Ad, it will enable a high level of gene expression in a cancer cell-specific manner. A critically important advantage of the ZFP approach is that ZFP targets the endogenous promoter itself, whereas antisense or small-interfering RNA should act on many copies of the mRNA transcripts. Because there are only two target sites (one in each allele of the VEGF locus), the concentration of ZFP transcription factor necessary to maintain downregulation might be independent of the rate of target gene expression. 19 In addition, the use of ZFP transcription factors would avoid the RNA interference that tends to induce interferon response. Further, unlike small-interfering RNA-or antibody-based strategies that suppress VEGF-A activity by inducing isoform-specific downregulation, an artificial transcription factor F435-KOX can concomitantly suppress the expression of all seven isoforms of VEGF-A. This is important because most tumor cell types produce several VEGF isoforms simultaneously, and it is known that VEGF signaling is fine-tuned by the differential expression of the VEGF isoforms. 25 In summary, in this study we have identified and demonstrated the utility of F435-KOX as a novel and potent ZFP transcription factor that can inhibit VEGF-A-mediated angiogenesis.
MAterIAls And MetHods
Cell lines and cell culture. All cancer cell lines and normal cell lines were cultured in Dulbecco's modified Eagle's medium (Gibco BRL, Grand Island, NY) supplemented with 10% fetal bovine serum (Gibco BRL), l-glutamine (2 mmol/l), penicillin (100 IU/ml), and streptomycin (50 μg/ml). HUVECs isolated from human umbilical cord veins by collagenase treatment were maintained and propagated as described earlier.
17
Generation of VEGF promoter-targeted transcriptional repressorexpressing Ads. In order to generate Ads expressing the VEGF promotertargeted transcriptional repressor F435-KOX at the E3 region, a F435-KOX gene excised from pLFD-F435-KOX 26 was subcloned into a pSP72-E3 Ad shuttle vector, 27 generating a pSP72-E3/F435-KOX shuttle vector. The newly constructed pSP72-E3/F435-KOX E3 shuttle vector was linearized with PvuI digestion, and then co-transformed with a replication-incompetent Ad total vector expressing green fluorescent protein (GFP) at the E1 region (pdl-∆E1-GFP), or replication-competent oncolytic Ad total vector (pdl-ΔB7), into Escherichia coli BJ5183 for homologous recombination, generating pAd-∆E1-KOX and pAd-ΔB7-KOX Ad vectors, respectively.
The proper homologous recombinant Ad plasmid DNA was digested with PacI and transfected into 293 cells to generate Ad-∆E1-KOX and Ad-ΔB7-KOX Ads. The E1-deleted replication-incompetent Ad, Ad-∆E1-GFP, and the replication-competent oncolytic Ad mutated in retinoblastoma binding sites of E1A and deleted in E1B regions, Ad-ΔB7, 7 were also prepared. All viruses were propagated in 293 cells, and the purification, titration, and quality analyses of all the Ads used were performed, as described earlier.
28
Tube formation assay. For the tube formation assay, 250 μl of growth factor-reduced Matrigel (Collaborative Biomedical Products, Bedford, MA) was transferred into a 16-mm diameter tissue culture well and polymerized for 30 minutes at 37 °C. HUVECs incubated in M199 media containing 1% fetal bovine serum for 6 hours were harvested after trypsin treatment and were suspended in the conditioned media from Ad-infected cells (U343 and U87MG) at a density of 2 × 10 5 cells/well. HUVECs were then plated onto the layer of Matrigel. The conditioned media from uninfected cells were used as controls. The cells were then allowed to form tubes for 20 to 24 hours at 37 °C, and photographed (×40). The area covered by the tube network was determined using an optical imaging technique, in which pictures of the tubes were scanned into Adobe Photoshop and quantified using Image-Pro Plus software (Media Cybermetics, Silver Spring, MD).
ex vivo assay of sprouting vessels from aortic ring. Aortas were removed from Sprague Dawley rats (6 weeks old). After the surrounding fibroadipose tissues had been removed, and after being rinsed with Hank's balanced salt solution buffer, the aortas were cut into 1-mm ring segments. The aortic rings were placed onto the Matrigel-coated plates (48 well) and overlaid with 50 μl of Matrigel. Conditioned media of 250 μl from Adinfected cells were then added to the wells, along with the conditioned media from uninfected cells as a control. On day 7, each ring was photographed (×40) and scores from 0 (least positive) to 5 (most positive) were assigned in a double-blinded manner. Viral production assay. U87MG cells were plated onto six-well plates at a density of 3 × 10 5 cells/well, and then infected with Ad-ΔB7 or Ad-ΔB7-KOX at an MOI of 1. At various time-points the cells and media were collected and freeze-thawed three times to release the viruses. The number of infectious particles present in the resulting supernatants was determined by performing a limiting dilution assay on 293 cells.
Cell-cycle analysis. Cells were infected with Ad-ΔB7 or Ad-ΔB7-KOX at an MOI of 1. At various time-points after infection, trypsinized and floating cells were pooled, washed with PBS, and fixed in 70% (vol/vol) ethanol. For assessment of DNA contents, the cells were stained with propidium iodide and counted using a fluorescence-activated cell sorter (Becton Dickinson, Sunnyvale, CA). The data from 10,000 cells were collected and cell-cycle distribution was analyzed using the CellQuest program (BD Biosciences Immunocytometry Systems, San Jase, CA). The subdiploid population was calculated in order to estimate the apoptotic cell population.
Assessment of the antitumor effect of F435-KOX-expressing Ads. Male athymic nu/nu mice at 5-6 weeks of age were obtained from Charles River (Yokohama, Japan). Tumors were implanted subcutaneously on the abdo- Histology and immunohistochemistry. For histology analysis, tumor tissue was fixed in IHC zinc fixative (formalin-free) (BD Pharmingen, San Diego, CA), embedded in paraffin, and cut into 3-μm sections (Wax-it, Vancouver, Canada). Representative sections were stained with hematoxylin and eosin, and then examined using light microscopy. For immunohistochemistry, slides were deparaffinized in xylene and then processed as described earlier. 29 All slides were counterstained with Meyer's hematoxylin.
Intratumoral microvessel density assessment. Blood vessels were counted as described earlier. 30 The most vascular area of tumors was identified on low power (×100), and the vessels were counted in ten high-power fields (×200). The data are presented as mean values ± SE for three tumors per group. TUNEL assay. Apoptosis was assessed by TUNEL assay as described earlier. 27 The apoptotic cells were visually identified in five selected fields and photographed at a magnification of ×200. More than 2,000 cells were counted to calculate the percentage of TUNEL-positive cells (apoptotic cell ratio).
Statistical analysis. The data are expressed as mean values ± SE, and the significance of differences between the mean values from the various groups was determined using the Mann-Whitney test (nonparametric rank sum test) with Stat View software (Abacus Concepts, Berkeley, CA). Differences were considered significant when P < 0.05.
